Actively Recruiting

Age: 18Years +
All Genders
NCT06503640

Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease (ANOCA-CMD)

Led by China-Japan Friendship Hospital · Updated on 2024-07-16

100

Participants Needed

1

Research Sites

130 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this observational study is to explore the incidence and effect on prognosis of coronary microvascular dysfunction in patients present of stable anginal symptoms, a clinical indication for invasive coronary angiography, and no hemodynamically significant epicardial coronary artery disease, defined as fractional flow reserve (FFR) \>0.80.

CONDITIONS

Official Title

Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease (ANOCA-CMD)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Presence of stable anginal symptoms requiring invasive coronary angiography
  • No significant blockage in main coronary arteries, defined as fractional flow reserve (FFR) over 0.80
Not Eligible

You will not qualify if you...

  • Acute myocardial infarction
  • Significant valvular heart disease
  • Advanced chronic kidney disease
  • Significant epicardial coronary artery stenosis over 70% needing intervention
  • Unable to provide written informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China, 100029

Actively Recruiting

Loading map...

Research Team

Z

Zhaoxue Sheng, Doctor

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here